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Abstract
Background: Medicines are a major driver of quality, safety, equity, and cost of care in low and middle-income
country health systems. Universal health coverage implementers must explicitly address appropriate use of medicines
to realize the health benefits of medicines, avoid wasting scarce resources, and sustain the financial viability of universal
health coverage schemes.
Discussion: Medicines are major contributors to the health and well-being of individuals and populations when used
appropriately, and they waste resources and endanger health when used unnecessarily or incorrectly. Stakeholders
need to balance inherently competing objectives in the pharmaceutical sector. Emerging and expanding UHC schemes
provide potential levers to balance competing system objectives.
To use these levers, sustainable universal coverage programs will require a) information systems that can track
medicines utilization, expenditures, and quality of medicines use; b) routine monitoring of indicators of medicines
availability, access, affordability, and use; c) policies and programs that facilitate appropriate medicines use by
prescribers, dispensers, and patients; d) transparency in setting priorities for medicines coverage under resource
constraints; and e) a system perspective to engage diverse actors.
As they operationalize paths toward universal health coverage and include targeted medicines coverage policies
and programs, systems can build on, and innovate, pharmaceutical policy frameworks and management tools
from different countries’ settings.
Summary: Ensuring that medicines which achieve important health outcomes are available, accessible to all, used
appropriately, and sustainably affordable is essential for realizing universal health coverage. Stakeholder cooperation
and use of information and financing system levers provide opportunities to work toward this goal.
Keywords: Universal health coverage, Medicines, Pharmaceutical benefit, Financial incentives, Health systems,
Quality of care
Background
On August 15, 2013, WHO Director General Dr. Chan
introduced the World Health Report 2013 saying
“Universal coverage means quality health care for all
delivered in ways that protect users from financial
ruin or impoverishment” and highlighted that “[T] he
challenge is to expand health services with constant atten-
tion to causes of waste and inefficiency that can be
reduced through smart policies and wise decisions [1].”
We argue that UHC implementers must explicitly
focus on medicines, which are one of the major drivers
of quality, safety, equity, and cost of care in low and
middle-income country (LMIC) health systems. We first
provide a brief overview of the typical medicines situ-
ation in LMICs; second, we describe the competing
objectives of pharmaceutical sector policies and suggest
that systems striving toward UHC have unique levers at
their disposal to balance these objectives; and third, we
highlight selected tools and approaches that systems
working toward UHC should consider when developing
targeted medicines policies and programs. We conclude
with key challenges that systems will face as they move
toward evidence-informed medicines coverage policies.
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Medicines and UHC - needs and opportunities
Medicines in health systems
Medicines are major contributors to the health and well-
being of individuals and populations when used appro-
priately, and they waste resources and endanger health
when used unnecessarily or incorrectly. Global medi-
cines spending has surpassed US $1 trillion per year [2]
and accounts for up to 67% of total health expenditures
in some countries [3], mostly paid out of pocket by con-
sumers. At the same time, medicines constitute three of
the top ten sources of waste of scarce health system re-
sources [4], due, among other factors, to underuse of
quality generic products [5]; taxes and tariffs increasing
product prices at different levels [6]; unreliable availability
of medicines in public sector facilities; [7] substandard
and falsified products in markets [8]; and inappropriate
use of medicines, including overuse of antibiotics (often
for children with respiratory infection or diarrhea) [9] and
underuse of proven therapies for chronic conditions (e.g.,
hypertension, diabetes) [10,11]. Meanwhile, households
face impoverishment due to paying for medicines [12,13]
while patients die prematurely because they lack access to
lifesaving medicines [14]. Providing access to novel high-
cost specialty medicines for prevalent chronic conditions
like cancers poses a growing ethical and economic chal-
lenge for policy makers in countries at all income levels.
Competing objectives of medicines policies
Stakeholders need to strike a balance between several com-
peting objectives in the pharmaceutical sector (Figure 1).
Ideally, all patients, particularly vulnerable ones, would
have access to the medicines they need according to
evidence-based treatment guidelines; products would be
of proven quality; appropriately prescribed medicines
would be available where and when patients need them;
and patients would take these medicines as needed to
achieve their clinical effects. In this ideal world, both
households and the health system would have the resources
to pay for necessary medicines, in light of competing de-
mands. To meet national concerns for a strong economy
and health security, local manufacturers would be profit-
able while providing high-quality products at costs that pa-
tients and systems could afford. Research-based companies
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Figure 1 Competing objectives in the medicines sector and selected approaches to balance them.
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stakeholders would adhere to transparent governance and
ethical business practices. However, these idealized pharma-
ceutical sector objectives inevitably compete in many ways.
For example, paying for medicines for people who cannot
afford them may exceed the resources of systems. Limiting
third party payments to preserve the financial sustainability
of health systems may increase out-of-pocket household
spending for medicines and limit appropriate use [15].
Potential UHC levers to balance objectives
Emerging and expanding UHC schemes have potential
levers to balance competing system objectives. Because
they enroll members and pay for their care, schemes
could access information on the demographic characteris-
tics, health care needs, and utilization patterns of mem-
bers. Because they employ or contract with providers,
UHC schemes can also know about the demographic
characteristics, prescribing patterns, and costs associated
with specific providers. In their role as financial intermedi-
aries, UHC schemes have leverage to determine what
types of care they pay for and how much they will pay,
and they can implement policies that provide incentives
for purchasing, prescribing, and using the most clinically
appropriate and safe medicines that are known to achieve
highly valued health outcomes. Since they pay for large
quantities of medicines, UHC schemes are also in a pos-
ition to negotiate product prices, dictate standards of
product quality, react to unethical promotion practices,
and demand supply channel efficiency.
Practically, most LMIC insurance schemes do not yet
use many of these levers [16,17]. Some schemes may not
know the demographics and clinical needs of their cov-
ered population. Schemes often have inefficient claims
processing systems, some based on paper forms, which
may make it difficult to access information about medi-
cines utilization in a timely way. Often, schemes limit
claims review primarily to detecting instances of fraud.
Working actively with members, providers, and manu-
facturers to set performance standards and shape pat-
terns of pharmaceutical care is currently beyond the
scope or capacity of most UHC systems. Historical ex-
perience [18] indicates that schemes tend to focus expli-
citly on medicines only when medicines expenditures
threaten the viability of the scheme, and they then focus
primarily on prices rather than quality medicines use.
Targeted medicines benefit strategies
We believe that not every available medicine for every
individual could or should be subsidized by a third party
payer. Targeted approaches to promote clinically appro-
priate, cost-effective medicines use require systems to
understand populations, clinical conditions, medicines,
settings for safe use, costs, and system capacity. Depending
on their values, goals, and resources, UHC systems may
choose to cover only specific medicines for defined condi-
tions in specific population groups, treated at the lowest
system level at which safe and effective care can be pro-
vided, and at costs that take into account members’ and
the system’s ability to pay.
Tools and approaches already exist that UHC schemes
in LMIC can adapt for use in their settings (Figure 1).
International [19] and local data on population disease
epidemiology, combined with information on current
patterns of care, can help to identify the most important
health conditions for which medicines are needed in a
given population. Given a set of priority health condi-
tions, evidence-based clinical guidelines [20] can be used
to determine the types of medicines needed, which pro-
vide a basis for medicine reimbursement lists. Health
technology assessment, budget impact analysis, and frame-
works for transparency can inform ethically challenging
decisions [21] about setting limits on covered therapies.
Participation in international product quality assurance
collaborations [22] can help ensure product quality, while
strengthening capacity for managing medicines in systems
[23] can improve the efficiency and reliability of supply.
Widely-used facility-based indicators of appropriate and
inappropriate medicines use in LMIC [9] could be adapted
for use with insurance claims data and expanded to assess
medicines use and expenditures for specific conditions.
To ensure financial viability, improve efficiency, and
facilitate appropriate use, LMIC insurance systems need
to pilot targeted medicines policies that provide incen-
tives to industry, drug distributors, procurement officers,
prescribers, dispensers, and patients, to supply and use
the most clinically appropriate medicines that achieve
valuable health outcomes in an affordable way. Policy
approaches, adopted mostly in high-income countries,
[24-27] typically address either cost or quality of care.
Pay-for-performance programs that financially reward
prescribers for achieving performance metrics related to
cost or quality and so-called “value-based” coverage pol-
icies that reduce the out-of-pocket cost for medicines
known to improve health outcomes combine both di-
mensions. While evidence is mixed on the effects of
pay-for-performance and value-based benefit policies in
high-income countries, evidence on the impacts of spe-
cific medicines benefit policies in LMIC is virtually non-
existent [16].
Given resource limitations, we suggest that most UHC
schemes in LMIC consider developing a minimum med-
icines benefit package that covers a selected list of cost-
effective first-line medicines for the most prevalent
conditions – many of which are essential medicines [28]
available as quality generic products. Given member de-
mand and pressure from providers, schemes also need
to decide whether and how to cover innovative, high-
Wagner et al. BMC Health Services Research 2014, 14:357 Page 3 of 6
http://www.biomedcentral.com/1472-6963/14/357cost medicines that have established clinical value but
that may benefit fewer patients. Different tools and ap-
proaches are needed to develop a minimum medicines
benefit and to make decisions about coverage of special-
ized high-cost medicines; in both cases, it is crucial for
the insurance system to monitor utilization, quality of
medicines use, and expenditures.
Key challenges
Better information
Information is the single greatest resource that well-
functioning UHC systems have at their disposal. How-
ever, in many systems, data may only be available about
medicines expenditures as a component of overall ex-
penditures, and sometimes even that is unmeasured.
Without more granular information about which medi-
cines are used, who prescribes them, how they meet the
care needs of specific patients, whether they achieve
intended population health outcomes, and whether they
are fairly and affordably priced, systems striving toward
UHC will find it difficult to ensure clinical quality, effi-
ciency, and safety in medicines coverage.
As UHC-targeting schemes expand, they will need to
use electronic payment systems. It is crucial that these
systems be designed to include the level of detail required
to actively manage a medicines benefit. The Table lists
illustrative performance indicators in four main pharma-
ceutical policy domains (Table 1). Routine information
systems should allow measurement of these or similar
indicators. However, high-end electronic systems take
resources and time to develop. In the meantime, other
readily available sources of routine data, such as prescrip-
tions and dispensing records at health facilities, can allow
stakeholders to generate information needed to make
evidence-informed decisions.
In sum, leaders working toward UHC need to strengthen
system capacity in benefit design, information technology,
pharmaceutical cost analysis, quality measurement, quality
assurance, and interpreting routine longitudinal data on
medicines availability, access, use, and expenditures.
More patient-centered systems
Most LMIC health systems were developed primarily to
treat acute conditions and provide inpatient care. The
Table 1 Examples of indicators to monitor medicines policies in UHC systems
Domain and question Sample indicator Possible data source
Availability of quality generic and innovative products
Does local industry produce a reliable supply
of needed high-quality, low-cost generics?
Volume and percent of locally-produced generics
that meet quality and price standards
Industry data
Quality test records
Do risk-sharing strategies between pharmaceutical
companies and payers to provide access to selected
high-cost medicines for selected patients achieve
intended outcomes, and what are unintended ones?
Percent patients with a target conditions who receive an
innovative product that results in expected health benefits
Industry risk sharing program
data
Equitable access
Do people receive the medicines they need? Percentage of people with a diagnosed chronic illness
who currently have an appropriate medicine available
to treat their condition
Household surveys
How does access to appropriate medicines differ
between groups of patients?
Percentage of patients with a given diagnosis who receive a
recommended first-line drug in different subgroups (categorized
by insurance scheme, geographic location, age group, gender,
race and ethnicity, socioeconomic status)
Prescriptions or dispensing
records at health facilities
Insurance claims records
Appropriate use
Are we overusing medicines? Percentage of primary care patients who receive an antibiotic Prescriptions or dispensing
records at health facilities
Insurance claims records
Are we underusing medicines? Percentage of patients with a chronic condition
(e.g., diabetes, hypertension) who receive at least
one of the recommended treatments
Prescriptions or dispensing
records at health facilities
Insurance claims records
Affordable costs
How much does the insurance scheme/health
system spend on medicines?
Medicines expenditures per member per month
(overall, by member category, by specific diagnoses,
by specific therapeutic categories)
Insurance reimbursement
records
What is the financial burden associated with
medicines spending in households?
Proportion of patients who indicate that they forego
medicines treatment or spend less on other basic
needs due to medicines costs
Household surveys
Wagner et al. BMC Health Services Research 2014, 14:357 Page 4 of 6
http://www.biomedcentral.com/1472-6963/14/357global epidemiologic transition and the increasing need
for efficient management of chronic illnesses now dictate
that health systems develop ways to provide continuous,
affordable, high quality care for life-long illnesses, mov-
ing care away from hospitals into the community and
taking greater advantage of non-physician providers includ-
ing nurses, pharmacists, and community health workers.
A challenge for UHC-targeting systems will be to link
community-based care – such as adherence support at
community providers’ offices, pharmacies, and homes -
with insurance financing.
Culture is an important determinant of medicines use.
LMIC insurance systems need to develop approaches
that promote appropriate traditional treatment and
avoid inappropriate care – such as using herbal remedies
rather than unnecessary antibiotics to soothe symptoms
of upper respiratory tract infections. Social marketing
efforts will be required to explain both the concept of
insurance, often unfamiliar in LMIC, as well as the
rationale for specific medicines benefit policies.
Everywhere, decision makers face challenging ethical
questions when setting spending priorities in light of
resource constraints. Values, population needs, cultural
contexts, the overall health care environment, and other
economic and social constraints must factor into decisions.
Approaches are certain to change over time, as population
needs, technologies, and systems change. Transparency in
decision making about medicines coverage [21] and ac-
commodating the preferences of civil society in benefit
discussions [29] will be key to maintaining public trust.
Health systems, and the broader national and global
systems of which they are a part, are complex and dy-
namic. Interventions by any one actor will impact the
behavior of others. Evaluating the impacts of medicines
policies in LMIC will require a system perspective [30]
to ensure that the intended and unintended effects of
policies are known and inform continued system learning.
Summary
LMIC working toward UHC have enormous potential to
improve health. To succeed, they need to adopt an explicit
system focus on sound, evidence-informed medicines pol-
icies. We highlight four key pharmaceutical system objec-
tives and outline policy options and essential information
needed to achieve them.
Abbreviation
UHC: Universal health coverage.
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